1. Home
  2. WWR vs CALC Comparison

WWR vs CALC Comparison

Compare WWR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.56

Market Cap

68.8M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.87

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
CALC
Founded
1977
2011
Country
United States
United States
Employees
20
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
19.1M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
WWR
CALC
Price
$0.56
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$1.92
$10.00
AVG Volume (30 Days)
862.8K
196.4K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.44
52 Week High
$3.75
$7.20

Technical Indicators

Market Signals
Indicator
WWR
CALC
Relative Strength Index (RSI) 51.83 60.37
Support Level $0.54 $0.53
Resistance Level $0.57 $2.39
Average True Range (ATR) 0.03 0.17
MACD -0.01 -0.03
Stochastic Oscillator 47.18 0.00

Price Performance

Historical Comparison
WWR
CALC

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: